Autonomix Medical, Inc. (AMIX) AI Stock Analysis

• Market Cap: $4.38M
• Dividend Yield: N/A
• Average Volume (3M): 31.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.03
• Revenue Growth: N/A
• EPS Growth: -10.29%
• Country: US
• Employees: 5
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 2,462,983
• 10 Day Avg. Volume: 12,736
• 30 Day Avg. Volume: 31,773
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Autonomix Medical, Inc. is under significant financial stress, with no revenue generation and a reliance on external financing. The technical indicators show a bearish trend, aligning with the negative financial outlook. The negative P/E ratio indicates valuation concerns, reinforcing the stock's overall low score.

Autonomix Medical, Inc. Business Overview & Revenue Model

Company Description

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

How the Company Makes Money

Autonomix Medical, Inc. generates revenue through the sale of its medical devices and software solutions to hospitals, clinics, and healthcare professionals. Key revenue streams include one-time sales of its proprietary hardware, subscription-based licensing for its software platforms, and service agreements for ongoing maintenance and support. The company also engages in strategic partnerships with healthcare providers and technology firms to expand its reach and enhance its product offerings. Additionally, AMIX may earn revenue from research and development collaborations and intellectual property licensing agreements.

Autonomix Medical, Inc. Financial Statement Overview

Summary

Autonomix Medical, Inc. is struggling to generate revenue, which impacts its overall financial health. The company’s reliance on financing activities highlights potential vulnerabilities in sustaining operations without generating revenue. While the low debt levels are a positive aspect, the inability to generate positive cash flow or revenue presents significant risks that need addressing for future sustainability.

Income Statement

Autonomix Medical, Inc. is facing significant challenges with its income statement. The company reports zero total revenue across all periods, leading to negative gross profit, EBIT, and net income. The lack of revenue generation reflects a critical concern for the company's growth prospects and profitability.

Balance Sheet

The balance sheet shows a reasonable equity position with a debt-to-equity ratio indicating low leverage, which is positive. However, the equity ratio has declined over the periods, suggesting an increase in liabilities relative to assets. The company appears to maintain a low level of debt, which mitigates risk, but there is little improvement in asset growth.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicative of operational challenges. The company is heavily reliant on financing activities to sustain operations, which could pose risks if external funding becomes less accessible. Although capital expenditure is minimal, the negative free cash flow suggests a need for strategic adjustments.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
-89.00K	-81.00K	0.00	0.00
	EBIT
-10.75M	-7.47M	-1.99M	-13.59M
	EBITDA
-13.27M	-15.27M	0.00	752.45K
	Net Income Common Stockholders
-13.63M	-15.43M	-1.99M	-13.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.82M	8.61M	864.62K	2.04M
	Total Assets
11.95M	9.41M	864.62K	2.05M
	Total Debt
1.13M	1.00M	0.00	0.00
	Net Debt
-10.69M	-7.61M	-864.62K	-2.04M
	Total Liabilities
2.25M	1.78M	220.59K	93.24K
	Stockholders Equity
9.71M	7.63M	644.03K	1.96M
Cash Flow		Free Cash Flow
-8.06M	-6.67M	-1.85M	-387.31K
	Operating Cash Flow
-8.04M	-6.65M	-1.85M	-387.31K
	Investing Cash Flow
-29.00K	-19.00K	0.00	0.00
	Financing Cash Flow
18.65M	14.41M	675.00K	2.43M

Autonomix Medical, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMIX, the sentiment is Neutral. The current price of 1.78 is above the 20-day moving average (MA) of 1.74, below the 50-day MA of 2.19, and below the 200-day MA of 8.47, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 49.64 is Neutral, neither overbought nor oversold. The STOCH value of 88.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMIX.

Autonomix Medical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$3.90B	-11.40	-15.29%	5.28%	19.55%	-44.95%
NUWE	49 Neutral	$3.90M	―	-229.24%	―	-1.40%	91.79%
SINT	42 Neutral	$4.48M	―	-174.07%	―	9.90%	94.56%
HSCS	41 Neutral	$3.46M	―	-163.47%	―	-100.00%	78.91%
AMIX	40 Neutral	$4.38M	―	-662.74%	―	―	-10.29%
RSLS	37 Underperform	$4.32M	―	-222.46%	―	-7.74%	93.25%

Autonomix Medical, Inc. Corporate Events

Autonomix Medical CEO Engages in Investor Series

On January 22, 2025, Autonomix Medical, Inc.’s CEO, Brad Hauser, participated in the Virtual Investor Closing Bell Series. The event was webcast live, with a replay available for 90 days, and marked a significant engagement with investors, offering insights into the company’s positioning and expectations. The conference presentation included forward-looking statements highlighting risks and uncertainties, emphasizing the need for stakeholders to review cautionary statements and disclosures filed with the SEC.